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Abstract
Objective
To determine tolerance to various risk scenarios associated with current multiple sclerosis
(MS) therapies.
Methods
People with MS from the North American Research Committee on Multiple Sclerosis Registry’s online cohort and the National Multiple Sclerosis Society were invited to complete
a questionnaire on tolerance to real-world risks associated with a hypothetical therapy. Multiple
risks levels were presented, including skin rash, infection, kidney injury, thyroid injury, liver
injury, and progressive multifocal leukoencephalopathy (PML).
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Results
Both PML and kidney injury had the lowest risk tolerance (RT) at 1:1,000,000, and thyroid and
infection risks had the highest tolerance at 1:1,000. Men, younger individuals, and participants
with greater disability reported a higher tolerance to all risk scenarios. Those who were currently taking an MS therapy reported higher tolerance than those not taking any therapy.
Participants taking infusion therapies reported high tolerance to all risks, and those taking
injectables reported a lower tolerance.
Conclusion
People with MS displayed a wide range of RT for MS therapies. Our study identiﬁed sex, age,
disability, and current disease-modifying therapy use to be associated with RT.
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Glossary
DMT = disease modifying therapy; MS = multiple sclerosis; NARCOMS = North American Research Committee on Multiple
Sclerosis; NMSS = National Multiple Sclerosis Society; PDDS = Patient Determined Disease Steps; PML = progressive
multifocal leukoencephalopathy; RT = risk tolerance.

Multiple sclerosis (MS) is an autoimmune disorder of the
CNS that often leads to neurologic disability.1 Although
there is no available cure for MS, the past 2 decades have
witnessed a dramatic development in disease-modifying
therapies (DMTs) that reduce MS relapse and delay disability. There are 15 approved therapies for MS treatment,
each with its own established beneﬁts and risks. The
injectables were the ﬁrst set of DMTs to be approved. They
reduce annualized clinical relapse rates by ≈30% and have
low risks.2,3 Intravenously administered natalizumab is
a highly eﬀective DMT but carries a risk of progressive
multifocal leukoencephalopathy (PML), an often fatal
brain infection.4–8 Additional infusion and oral therapies
with their own speciﬁc eﬃcacy and safety proﬁles are
available, with some also associated with PML risk.
An important aspect of the medical decision-making process
for MS treatment is each individual’s tolerance to the inherent risks associated with currently available DMTs. A few
studies have assessed the risk tolerance (RT) of people with
MS9,10 and have found that PML was regarded as an important concern by both people with MS and their clinicians.
In an earlier study on RT,11 we found male sex and increased
disability to be predictors of higher tolerance to 2 treatment
scenarios: natalizumab and a hypothetical treatment that
cured MS. While this study compared only 2 treatment
scenarios, one being hypothetical, a direct comparison of the
tolerance to not just PML but other risks associated with
various DMTs has not been made. It is not known how RT
to individual risks would inﬂuence treatment preference. In
light of the increasing number of DMTs with a wide range of
risks, we expanded on our initial study11 to explore RT to 6
real-world risks that are associated with current DMTs: skin
rash, infection, kidney injury, thyroid injury, liver injury,
and PML.

Methods
Focus group
Focus groups involving people with MS and their care
partners were conducted at 4 geographically distant MS
clinics across the United States to gain insights into factors
related to their preferences while choosing an MS DMT.
Focus groups were structured using a moderator guide to
understand values and perceptions of living with MS and
considerations when making decisions about MS therapies.
Discussions were facilitated by an experienced moderator
and audio recorded for data capture. Data analysis was an
iterative and progressive process of data immersion, open
Neurology.org/N

coding, constant comparison, documentation, and theme
identiﬁcation.
Survey design and testing
Survey questions on DMT risk preferences and decision
making were designed to incorporate the themes that
emerged from the focus groups. Semistructured in-person
cognitive interviews were conducted with 6 people with MS
with diverse MS history to test the instrument for clarity and
comprehension.
The survey was ﬁnalized on the basis of the ﬁndings from
the cognitive interviews. In the ﬁnal survey, individual risk
preference and acceptance were evaluated by describing
a hypothetical therapy with a ﬁxed beneﬁt of 50% reduction
in clinical relapse rate and 30% reduction in disability
progression. This eﬃcacy is in the range of eﬃcacy reported
for the majority of currently used MS therapies. Using
a single eﬃcacy and varying only the types of risks reduced
survey burden and potential confusion by participants. A
standard gamble paradigm12,13 was used to evaluate the RT
to each of the 6 risks. The risks were described as follows:
(1) risk of infection such as bladder and respiratory, which
may occasionally require hospitalization; (2) thyroid injury,
which may require lifelong thyroid medication; (3) skin
rash, which may be serious enough to require hospitalization; (4) liver injury, which may require repeated blood test
monitoring; (5) kidney injury, which may require lifelong
dialysis; and (6) risk of PML, which could be fatal. For each
of the 6 risks, the odds of that risk were changed iteratively
to identify the maximum RT for each risk for each participant. The survey was reviewed and approved by the Institutional Review Board at the University of Alabama at
Birmingham.
Survey administration
The North American Research Committee on Multiple
Sclerosis (NARCOMS) Registry maintains a global longitudinal database of conﬁdential information voluntarily
submitted by >38,000 people with MS. In 2010 and 2011,
we had used the registry for a survey on patient decision
making and RT. All 3,755 active NARCOMS Registry
participants who had participated in either or both of the
earlier surveys were invited via e-mail to participate in the
new RT survey. The survey ran from March 3, 2016, to
April 8, 2016. NARCOMS participants received up to 2
reminder e-mails to complete the survey. In addition, a link
to the survey was available between March 17, 2016, and
April 16, 2016, through the National Multiple Sclerosis
Society (NMSS) website for anyone with MS who wished
Neurology | Volume 92, Number 14 | April 2, 2019
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to participate in the survey. To avoid overlap between
NMSS and NARCOMS participants, NMSS participants
who indicated to also be a NARCOMS registrant were
asked to complete the survey through the NARCOMS link.
For both NARCOMS- and NMSS-administered surveys,
online consent was obtained before survey administration,
and NARCOMS staﬀ were available via telephone and
e-mail throughout the survey period to assist study
participants.
A preset iterative algorithm was used to identify the maximum
RT for each participant (ﬁgure 1). The lowest anchor point
was 0 (never take any risk for the beneﬁt), and the highest was
1 (will take any risk for the beneﬁt). The survey collected
demographic characteristics, socioeconomic information,
DMT use, and disease characteristics, including disability
measured with the Patient Determined Disease Steps
(PDDS).14
Statistical analysis
To be included in the analysis, participants were required
to have answered questions about their sex, disease duration, and PDDS and at least 4 of the 6 risk scenario
questions. Missing data were left missing and were not
imputed. Descriptive statistics were used to summarize
demographic and RT results. Comparison of median RT
used unadjusted Wilcoxon-Kruskal-Wallis test, with nonparametric multiple-comparisons test using the SteelDwass–adjusted method. Comparison of proportions used

likelihood ratio χ 2 or Fisher exact test, as applicable. To
compare risk levels according to DMT type, DMTs were
classiﬁed as injectable (daclizumab, glatiramer acetate,
interferon beta-1a/1b, peginterferon beta-1a), oral (dimethyl fumarate, ﬁngolimod, laquinimod, teriﬂunomide),
or infusion (alemtuzumab, mitoxantrone, natalizumab).
To determine risk levels adjusted for sex, age group, disability level, and current DMT status, participants’ RT was
allocated to willingness to accept large (RT 1:50, regardless of death), moderate (RT 1:1,000–1:100), low (RT 1:
50,000–1:2,000), or minimal (no risk, 1:100,000) risk for
each condition and evaluated with an ordinal logistic regression. JMP Pro 12/13 (SAS Institute, Inc, Cary, NC)
was used for analysis, and values of p < 0.05 were considered meaningful.
Data availability
Because of ongoing data analyses, the raw data are currently
not available. Interested qualiﬁed investigators should direct
inquiries to the corresponding author.

Results
Focus groups
Thirty-six people with MS and 24 care partners participated in 8
focus groups. Of those with MS, 75% were female, 81% were
white, mean age was 53 years, 50% were employed, and 39%
received disability insurance. The majority of support partners

Figure 1 Standard gamble risk tree

Risk levels used to evaluate the risk tolerance (RT) of study participants to various therapeutic scenarios, starting at 1:1,000. Participants would answer yes (Y)
or no (N) to incremental or decreasing risk levels on the basis of prior responses. An RT value was assigned at the last acceptable risk level indicated with
a “yes.”
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Table Respondent sociodemographic and disease
characteristics

Table Respondent sociodemographic and disease
characteristics (continued)

Characteristics

All

DMT current

Characteristics

No. (%)

3,371 (100)

1,798 (53.5)

a

55.1 (11.1)

53.4 (10.8)

a

2,668 (79.1)

1,448 (80.5)

Age, mean (SD), y

Female sex, n (%)
a

Race, n (%)

All

DMT current

PDDS score 7, wheelchair/scooter

271 (8.0)

90 (5.0)

PDDS score 8, bedridden

11 (0.3)

1 (0.1)

Current DMT, n (%)c

1798 (53.3)

Interferon β-1d

391 (21.7)

White

3,119 (92.5)

1,672 (93.0)

Glatiramer acetate

408 (22.7)

Black

60 (1.8)

38 (2.1)

Teriflunomide

112 (6.2)

Other/multiple

151 (4.5)

71 (4.0)

Fingolimod

256 (14.2)

Dimethyl fumarate

391 (21.7)

Natalizumab

202 (11.2)

Employment, n (%)a
Full-time

999 (31.4)

623 (34.8)

Part-time

339 (10.7)

199 (11.1)

Not employed

1,840 (57.9)

876 (48.9)

3,130 (98.6)

1,680 (93.8)

Married/cohabitating

2,301 (68.3)

1,235 (68.7)

Divorced/separated/widowed

524 (15.5)

270 (15.0)

Never married

331 (9.8)

187 (10.4)

Yes

2,445 (72.8)

1,306 (73.0)

If yes, spouse/partner

2,158 (88.7)

1,157 (89.0)

Another family member

223 (9.2)

115 (8.9)

Friend

51 (2.1)

28 (2.2)

187 (5.9)

78 (4.4)

16.6 (9.8)

15.5 (9.1)

RRMS

2,035 (60.5)

1,281 (71.3)

Progressive MS

930 (27.6)

349 (19.4)

CIS and unknown

401 (11.9)

168 (9.3)

1,047 (31.4)

471 (26.4)

Median PDDS score (IQR)

3 (1–5)

3 (1–4)

PDDS score 0, normal

636 (18.9)

385 (21.4)

PDDS score 1, mild disability

543 (16.1)

315 (17.5)

PDDS score 2, moderate disability

291 (8.6)

156 (8.7)

PDDS score 3, gait disability

478 (14.2)

278 (15.5)

PDDS score 4, early cane

465 (13.8)

260 (14.5)

PDDS score 5, late cane

327 (9.7)

158 (8.8)

PDDS score 6, bilateral support

349 (10.1)

155 (8.6)

Health insurance, n (%)a
Marital status, n (%)

Primary caregiver, n (%)

Smoking every day, n (%)a
MS duration, mean (SD), y
Current MS type, n (%)

a

Abbreviations: CIS = clinically isolated syndrome; DMT = disease-modifying
therapy; IQR = interquartile range; MS = multiple sclerosis; PDDS = Patient
Determined Disease Steps; RRMS = relapsing-remitting multiple sclerosis.
a
p < 0.05 for group comparison.
b
Progression in prior 6 months: “Over the last 6 months, have your MS
symptoms worsened in a gradual, progressive manner (not due to relapses
or exacerbations)? Yes/No/Unsure.”
c
Percent may total >100% because participants may have indicated >1
current DMT.
d
Interferon beta-1a and -1b and peginterferon beta-1a.

were spouses (75%); 96% were white; 50% were female; and
their mean age was 60 years. The main themes that emerged
from the focus groups were risk of adverse events, quality of life,
status of their MS, involvement of care partners, and decision
making control.
Figure 2 Survey CONSORT diagram

a

Progression in prior 6 mo, n (%)a
Disability, n (%)a,b

Neurology.org/N

A Consolidated Standards in Reporting Trials (CONSORT) diagram of survey
invitation through the North American Research Committee on Multiple
Sclerosis (NARCOMS) Registry and National Multiple Sclerosis Society
(NMSS) website, participants who initiated the survey, and analysis cohort.
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Participant characteristics
The survey was successfully completed by 3,171 participants
(ﬁgure 2). The table summarizes participant characteristics
and disease status. Overall, 79% of the survey participants
were female, 92.5% were white, mean age was 55.1 (±11.1)
years, and mean disease duration was 16.6 (±9.8) years. A large
proportion of the participants (71.5%) reported lower levels of
disability (PDDS score 0–4), and only 0.3% of the participants
reported to be bedridden (PDDS score 8). In all analyses
PDDS scores 7 and 8 were combined. Almost all participants reported having health insurance, and a large proportion of the participants (88.7%) reported having
a spouse/partner to assist in caregiving. About half the
participants reported current use of DMT (53.3%) with
similar proportions on oral (22.1%) and injectable (22.9%)
DMTs and only 8.6% on infusion therapies (table). About
10% of the participants reported to have never used any
DMTs for their MS treatment.

Unadjusted associations
Unadjusted median risk was compared for sex, age groups
(<41, 41–50, 51–60, 61–70, ≥71 years), current disability,
DMT history (current or past) of use, and, if currently taking
a DMT, by type of DMT (injectable, oral, infusion) (table e-1
available from Dryad, doi.org/10.5061/dryad.tg142pt).
By sex

Male participants reported a high tolerance (1:1,000) to all
complications except kidney injury (1:50,000) and PML
(1:100,000). For all 6 risk complications, female participants
consistently reported 2- to 20-fold lower RT (ﬁgure 4A and
table e-1 available from Dryad, doi.org/10.5061/dryad.
tg142pt). Female participants reported an RT of 1:2,000 for
both infection and thyroid injury (2-fold lower than male participants), while the RT for both kidney injury and PML for the
female participants was 1:1,000,000 (20- and 10-fold lower).
By age

Overall RT
Participants reported the highest tolerance for infection or
thyroid complications (median RT 1:1,000 for both, ﬁgure 3
and table e-2 available from Dryad, doi.org/10.5061/dryad.
tg142pt). The next highest tolerance was for skin rash (1:
2,000), followed by liver injury (1:10,000). The lowest RT
was for both kidney injury and PML at 1:1,000,000.

Tolerance for liver injury, kidney injury, and PML decreased
with age, whereas the RTs for infection, skin rash, and thyroid
injury were not signiﬁcantly diﬀerent across age groups (ﬁgure
4B and table e-1 available from Dryad, doi.org/10.5061/dryad.
tg142pt). Participants who were <41 years of age reported an
RT of 1:2,000 for liver injury, while the rest of the age group
reported an RT of 1:10,000. The tolerance pattern to kidney

Figure 3 Overall RT by various risks

Median risk tolerance (RT) for each of the risk scenarios is indicated by solid bars; 25th and 75th percentiles of RTs are indicated by capped lines. PML =
progressive multifocal leukoencephalopathy.

e1638
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Figure 4 Unadjusted association of median RT to participant characteristics

Median risk tolerance (RT) by (A) sex, (B) age, (C) Patient Determined Disease Steps, (D) disease-modifying therapy (DMT) use, and (E) DMT type. In all, the
overall median RT is indicated by gray bars, and lines indicate median RT by participant characteristics. PML = progressive multifocal leukoencephalopathy.

injury and PML followed a similar pattern, with participants
<41 years of age having a high RT of 1:100,000 and those >51
years of age having a low RT of 1:1,000,000.
Neurology.org/N

By disability

In general, RT increased with disability, with higher levels of
disability accepting signiﬁcantly higher levels of risk compared
Neurology | Volume 92, Number 14 | April 2, 2019
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Figure 5 Percent accepting risk group by condition

Graph illustrates percent accepting risks
for each of the 6 scenarios when risk tolerance (RT) is stratified into 4 groups of
increasing RT values: minimal, low, moderate, and large. PML = progressive multifocal leukoencephalopathy.

to a lower PDDS level across all 6 risk scenarios (ﬁgure 4C).
In general, participants who reported minimal or no disability
(PDDS score 0) had the least tolerance to all risks, and participants who reported a PDDS score ≥6 had the highest
tolerance to all risks. Those with PDDS scores of 1 to 2 and 3
to 5 had similar RTs for infection, skin rash, and liver injury;
those with PDDS scores of 0 and 1 to 2 had similar RTs for
skin, liver, and PML (table e-3 available from Dryad, doi.org/
10.5061/dryad.tg142pt).

not accept any risk), whereas those using infusion DMTs
were quite tolerant of PML (RT = 1:1,000). Those taking
infusion DMTs were the only participants who regarded
risk of kidney injury (RT 1:500,000) to be higher than that
of PML (RT 1:1,000, table e-1 available from Dryad, doi.
org/10.5061/dryad.tg142pt); all other participants
reported kidney injury risk to be either the same as that for
PML or 2-fold lower.
Other characteristics

By DMT history

Current DMT users exhibited 2- to 10-fold higher RTs than
those not currently taking any DMT for their MS treatment
(ﬁgure 4D). RT to infection, liver injury and PML risks
appeared to be signiﬁcantly higher (p < 0.0001) in current
DMT users. The diﬀerence observed in the RT to thyroid
injury and skin rash was not statistically signiﬁcant.
By type of current DMT use

The tolerance within current DMT users was further examined on the basis of DMT type (injectables, orals or
infusion). Of current DMT users (n = 1,798), there was
a similar proportion of injectable (43.0%) and oral
(41.4%) users and a smaller proportion who were on infusion therapies (12.2%). Participants who were on injectable DMTs had the least tolerance to all 6 risk
scenarios, and participants who were on infusion DMTs
had the highest RT (ﬁgure 4E). Participants using injectable DMTs were very unlikely to accept PML risks (will
e1640
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Neither disease duration nor smoking was associated with RT
in any of the risk scenarios (table e-1 available from Dryad,
doi.org/10.5061/dryad.tg142pt).
Adjusted risk models
The proportion of participants in each RT category (willingness to accept large, moderate, low, or minimal risk) for
each condition is shown in ﬁgure 5. For infection, thyroid,
skin, and liver, the conclusions for the adjusted models
were similar to the unadjusted associations: men, older
individuals, those with higher disability levels, and current
DMT users were more willing to accept a larger amount of
risk. For kidney and PML, nearly two-thirds of participants
were willing to accept only minimal RT. Therefore, adjusted models looked at minimal vs higher RT and were
similar to unadjusted results: men, older individuals, those
with higher disability levels, and current DMT users were
more willing to accept a larger amount of risk (data not
shown).
Neurology.org/N

Discussion
We explored the views of people living with MS regarding their
tolerance to various real-world risks associated with currently
available therapies. We used a hypothetical therapy with a ﬁxed
realistic beneﬁt and varied the complication to characterize RT
associated with 6 diﬀerent complications: infection, thyroid, skin,
liver, kidney, and PML.
Participants exhibited highest tolerance for infection and
thyroid injury (RT 1:1,000 for both) and the least tolerance
for kidney injury and PML (1:1,000,000 for both, ﬁgure 2).
Although RT was variable among people with MS, a large
proportion were risk averse. Depending on the speciﬁc
complication, 17% to 39% of the participants were unwilling
to assume any risk for a beneﬁcial therapy (indicated as
“none” in table e-2, available from Dryad, doi.org/10.5061/
dryad.tg142pt). In contrast, <2% of the participants were
willing to accept any risk for the beneﬁt of a therapy. An RT of
1:1,000 corresponds roughly to the midpoint in our risk tree
(ﬁgure 1), and more than half the participants (50%–76%)
exhibited a median RT that was <1:1,000.
For all RT scenarios, men were more tolerant to risks than
women. In addition, increasing age was associated with
lower RT. Speciﬁcally, older participants (age >51 years)
reported lower tolerance to liver, kidney, and PML risks than
participants who were <41 years old. Age of 41 to 50 years
appeared to be a transition point in RT, with the median RT
among participants >50 years of age remaining relatively
stable. Greater disability was associated with greater RT in all
scenarios. Participants with no disability (PDDS score 0) did
not tolerate any PML risk, whereas those who were wheelchair bound or bedridden (PDDS score >7) had a median
RT of 1:10,000 for PML. The shift in RT was most evident
around PDDS score 5; participants with a PDDS score ≥6
had a signiﬁcantly higher tolerance to all risks compared to
those with lower PDDS levels (table e-3 available from
Dryad, doi.org/10.5061/dryad.tg142pt). About half of the
participants reported current DMT use and exhibited greater
RT in all scenarios. Willingness to accept risks was also
inﬂuenced by DMT type. Participants taking oral and infusion DMTs reported a greater RT compared to those using
injectables in all scenarios. Oral and infusion DMT users had
similar RTs except for PML risk, for which participants
taking infusion DMTs had a greater tolerance.
About two-thirds of the participants in this study also participated in a similar RT survey administered through NARCOMS in 2010 to 2011.11 The earlier survey used the same
treatment beneﬁt (50% reduction in relapse rate and 30%
slowing in disability progression) and assessed RT to the risk
of PML. The median RT for PML in the earlier survey was 1:
10,000, much lower than in this study. The reason for this shift
in RT over time is unclear but may be related to new perceptions regarding PML. In addition, the earlier survey
assessed only PML risk, whereas in this survey, we have
Neurology.org/N

included 5 additional risk scenarios with the same therapeutic
beneﬁt. Thus, contextual eﬀects from assessing PML risk
along with other less serious risks such as skin rash or thyroid
dysfunction may have shifted the PML RT.
Only a few other studies have evaluated RT in people with
MS. One study surveyed 651 people with MS using the stated
choice method for 3 diﬀerent scenarios (PML, liver failure,
and leukemia) and found the lowest RT to PML, followed by
liver failure and leukemia. Our results parallel the study
ﬁndings of low tolerance to PML followed by liver injury.9
Another study used the standard gamble paradigm to evaluate
RT to death.15 Those investigators observed male sex, greater
disability, and longer disease duration to be associated with
greater tolerance to risk of death. We found a similar association with sex and disability but not disease duration. That
study was relatively small (n = 223) and focused on an urban
MS specialty center, whereas our study was larger, included
participants from across the United States, and more closely
approximates the typical MS patient population.
There are several limitations to this study. We used a ﬁxed beneﬁt
of therapy: 50% reduction in relapse rate and 30% slowing in
disability. While this beneﬁt represents a realistic estimate for an
MS DMT, it is likely that RT to the same beneﬁts may vary
according to treatment beneﬁt. Although 6 of the most commonly associated risk scenarios were studies, many other risks
were not assessed. In some of our analyses, we combined DMTs
by administration route, which may be an oversimpliﬁcation
because some DMTs with the same administration route likely
have somewhat diﬀerent eﬃcacies (i.e., oral DMTs).
Guiding people with MS to the best treatment for them
requires not only an assessment of the beneﬁts and risks of
a treatment but also an awareness of their preferences regarding which risks are considered acceptable. This study
provides a detailed understanding of how diﬀerent real-world
risks are perceived by people living with MS and outlines
some factors that are associated with these risks. Our ﬁndings
indicate that RT diﬀers according to sex, age, disability level,
and current DMTs; therefore, treatment preferences across
these characteristics also are likely to be diﬀerent. At the same
time, there was very broad RT within any individual sex, age,
disability level, and current DMT, which highlights the heterogeneity of RT. Understanding risk perception and RT, as
well as its heterogeneity, can ultimately lead to greater satisfaction with treatment choices and perhaps treatment
adherence.
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